Abstract YO39
Case summary
Background: Follicular thyroid carcinoma commonly presents with hematogenous metastasis to the lung and bone and rarely to the kidney. We report a case of a 61-year old woman with a metastatic follicular thyroid carcinoma to the kidney. This case report shows how a systematic approach on a patient with a renal mass can lead to a diagnosis of an unexpected primary cancer.
Case Report: A 61-year old female presented with progressively enlarging back mass. Whole abdominal ultrasound revealed right renal mass; chest CT scan showed multiple heterogeneously varisized pulmonary nodules. Ct-guided fine needle aspiration biopsy of the lung nodule was compatible with a non-small cell carcinoma. Immuno-histochemistry was positive for CK7, TTF1 and thyroglobulin and CK 20 negative favoring metastatic thyroid carcinoma. Ultrasound-guided core needle biopsy of the renal mass was compatible with thyroid carcinoma, metastatic (thyroglobulin positive). The final histopathology report after thyroidectomy was non-invasive follicular thyroid neoplasm with papillary-like nuclear features. The patient received radioactive iodine and is now with better quality of life.
Discussion: Metastatic follicular thyroid carcinoma is a rare phenomenon with only 25 cases reported in the English literature to date. Johnson et al in 1982 reported a case of follicular thyroid carcinoma with metastasis to the kidney 37 years after resection of the primary tumor. In a study by Parameswaran in 2016 on patterns of metastasis in follicular thyroid carcinoma, they found out that 40% of cases metastasized at a median of 4.5 years after initial thyroidectomy, lungs being the most common site followed by bone (25%), regional lymph nodes (13%) and brain (12%). None of the said cohort had metastasis to the kidney. The best management of FTC presenting as metastatic disease should be managed aggressively with total thyroidectomy followed by RAI which was done in our patient.
Conclusion: Given the rarity of thyroid metastasis to the kidney, a diagnostic dilemma for this case was a challenge. This case provides new data to clinicians that thyroid carcinoma can metastasize to the kidney and may mimic renal cell carcinoma although rarely reported.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract